Works matching AU Tokat, Unal Metin

Results: 11

Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer.

Published in:

Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42736-y

By:

Saatci, Ozge;
Cetin, Metin;
Uner, Meral;
Tokat, Unal Metin;
Chatzistamou, Ioulia;
Ersan, Pelin Gulizar;
Montaudon, Elodie;
Akyol, Aytekin;
Aksoy, Sercan;
Uner, Aysegul;
Marangoni, Elisabetta;
Sajish, Mathew;
Sahin, Ozgur

Publication type:

Article

Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer.

Published in:

Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42736-y

By:

Saatci, Ozge;
Cetin, Metin;
Uner, Meral;
Tokat, Unal Metin;
Chatzistamou, Ioulia;
Ersan, Pelin Gulizar;
Montaudon, Elodie;
Akyol, Aytekin;
Aksoy, Sercan;
Uner, Aysegul;
Marangoni, Elisabetta;
Sajish, Mathew;
Sahin, Ozgur

Publication type:

Article

Targeting LINC00152 activates cAMP/Ca<sup>2+</sup>/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.

Published in:

Cell Death & Disease, 2024, v. 15, n. 6, p. 1, doi. 10.1038/s41419-024-06814-3

By:

Saatci, Ozge;
Alam, Rashedul;
Huynh-Dam, Kim-Tuyen;
Isik, Aynur;
Uner, Meral;
Belder, Nevin;
Ersan, Pelin Gulizar;
Tokat, Unal Metin;
Ulukan, Burge;
Cetin, Metin;
Calisir, Kubra;
Gedik, Mustafa Emre;
Bal, Hilal;
Sener Sahin, Ozlem;
Riazalhosseini, Yasser;
Thieffry, Denis;
Gautheret, Daniel;
Ogretmen, Besim;
Aksoy, Sercan;
Uner, Aysegul

Publication type:

Article

Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers.

Published in:

Current Oncology, 2024, v. 31, n. 10, p. 5838, doi. 10.3390/curroncol31100434

By:

Tokat, Ünal Metin;
Adibi, Ashkan;
Aydın, Esranur;
Özgü, Eylül;
Bilgiç, Şevval Nur;
Tutar, Onur;
Özbek Doğançay, Merve;
Demiray, İrem;
Demiray, Mutlu

Publication type:

Article

Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety.

Published in:

Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241297101

By:

Tokat, Ünal Metin;
Bilgiç, Şevval Nur;
Aydın, Esranur;
Adibi, Ashkan;
Özgü, Eylül;
Tutar, Onur;
Demiray, Mutlu

Publication type:

Article

Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations.

Published in:

Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241247023

By:

Aydın, Esranur;
Tokat, Ünal Metin;
Özgü, Eylül;
Adibi, Ashkan;
Tutar, Onur;
Kurzrock, Razelle;
Demiray, Mutlu

Publication type:

Article

PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview.

Published in:

Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231213841

By:

Adibi, Ashkan;
Tokat, Ünal Metin;
Özgü, Eylül;
Aydın, Esranur;
Demiray, İrem;
Demiray, Mutlu

Publication type:

Article

Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC by dual immunotherapy and sorafenib.

Published in:

Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1405170

By:

Aydın, Esranur;
Tokat, Ünal Metin;
Adibi, Ashkan;
Özgü, Eylül;
Bilgiç, Şevval Nur;
Demiray, Mutlu

Publication type:

Article

Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.

Published in:

Breast Cancer Research & Treatment, 2022, v. 193, n. 2, p. 331, doi. 10.1007/s10549-022-06569-5

By:

Assidicky, Ridho;
Tokat, Unal Metin;
Tarman, Ibrahim Oguzhan;
Saatci, Ozge;
Ersan, Pelin Gulizar;
Raza, Umar;
Ogul, Hasan;
Riazalhosseini, Yasser;
Can, Tolga;
Sahin, Ozgur

Publication type:

Article

Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.

Published in:

Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-16199-4

By:

Saatci, Ozge;
Kaymak, Aysegul;
Raza, Umar;
Ersan, Pelin G.;
Akbulut, Ozge;
Banister, Carolyn E.;
Sikirzhytski, Vitali;
Tokat, Unal Metin;
Aykut, Gamze;
Ansari, Suhail A.;
Dogan, Hayriye Tatli;
Dogan, Mehmet;
Jandaghi, Pouria;
Isik, Aynur;
Gundogdu, Fatma;
Kosemehmetoglu, Kemal;
Dizdar, Omer;
Aksoy, Sercan;
Akyol, Aytekin;
Uner, Aysegul

Publication type:

Article

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2 -amplified metastatic breast cancer refractory to trastuzumab deruxtecan.

Published in:

2025

By:

Tokat, Ünal Metin;
Adibi, Ashkan;
Aydın, Esranur;
Bilgiç, Şevval Nur;
Özgü, Eylül;
Tutar, Onur;
Demiray, Mutlu

Publication type:

Case Study